Pliant Therapeutics, Inc.
(NASDAQ : PLRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.43%688.872.6%$679.29m
MRNAModerna, Inc. 0.15%118.250.0%$616.94m
AMGNAmgen, Inc. -1.32%225.401.4%$605.62m
BIIBBiogen, Inc. 1.03%267.001.8%$554.62m
GILDGilead Sciences, Inc. -2.19%61.691.0%$514.54m
VRTXVertex Pharmaceuticals, Inc. -1.11%289.541.9%$401.56m
ILMNIllumina, Inc. -1.56%190.793.2%$338.76m
SNSSSunesis Pharmaceuticals, Inc. 4.40%4.270.7%$298.49m
SAVACassava Sciences, Inc. -2.90%41.820.0%$189.63m
BNTXBioNTech SE 0.96%134.880.0%$112.19m
NVAXNovavax, Inc. -1.99%18.2075.6%$84.03m
BMRNBioMarin Pharmaceutical, Inc. -0.34%84.774.2%$82.56m
NRBONeuroBo Pharmaceuticals, Inc. 9.35%13.690.0%$78.90m
PRTAProthena Corp. Plc 1.95%60.6313.8%$78.20m
CRSPCRISPR Therapeutics AG 1.33%65.350.6%$76.10m

Company Profile

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.